Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1512226 | 0.89 | GRM2 (0.47) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1245956 | 0.87 | KMT2A (0.44) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1495305 | 0.87 | GRM2 (0.50) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1245490 | 0.86 | GRM2 (0.56) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1495289 | 0.86 | GRM2 (0.53) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1495124 | 0.86 | GRM2 (0.53) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1495292 | 0.85 | GRM2 (0.45) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1246280 | 0.84 | GRM2 (0.47) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1246625 | 0.83 | GRM2 (0.41) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL1246550 | 0.83 | POLB (0.43) | GRM2KDM4EMAPTSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065669-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-17 | — | — | US | claimed |
| US-20110065669-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065669-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065669-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | GRM2, GRM1, GRM3 | GRM2 1/4885KDM4E 2667/4885MAPT 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.